$115.42
+10%Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
PVLA • NASDAQ
| Palvella Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-41.7M | -17.4M | 18.7M | -27.6M | -45.7M | -37.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 2.4M | 2.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 164K | |
6.4M | 830K | 603K | 427K | 0.0 | 0.0 | |
6.5M | 6M | -29.8M | 10.7M | 5.2M | 5.4M | |
3.8M | -193K | -3.1M | 1.6M | 30.5M | -16.4M | |
-25M | -10.8M | -13.7M | -14.8M | -7.7M | -45.9M | |
INVESTING ACTIVITIES | ||||||
(0.0) | (0.0) | (0.0) | (0.0) | -949K | -2.7M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -41.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 83.4M | |
(0.0) | (0.0) | (0.0) | (0.0) | -949K | (39.2M) | |
FINANCING ACTIVITIES | ||||||
763K | 0.0 | 0.0 | 0.0 | 59.1M | 10.1M | |
0.0 | 78.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.4M | 8.7M | 5M | 34K | 0.0 | 0.0 | |
-660K | 87.1M | 5M | 9.6M | 59.1M | 10.1M | |
CASH FLOW SUMMARY | ||||||
46K | 3K | 0.0 | 0.0 | -3.2M | 4.7M | |
-25.6M | 76.3M | -8.7M | -5.3M | 47.3M | 8.2M | |
83.6M | 7.4M | 16.1M | 21.3M | 70.4M | 62.3M | |
58M | 83.6M | 7.4M | 16.1M | 117.8M | 70.4M | |
-25M | -10.8M | -13.7M | -14.8M | -8.6M | -48.6M |
PVLA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 |
Continue your PVLA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.